Goldman Sachs Group Inc Ardelyx, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Ardelyx, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,003,536 shares of ARDX stock, worth $26.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,003,536

Previous 2,378,738 68.31%

Holding current value

$26.1 Million

Previous $11.7 Million 34.37%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.28 - $5.51 $5.33 Million - $8.95 Million	1,624,798 Added 68.31%	4,003,536 $15.7 Million
Q1 2025 May 09, 2025	BUY	$4.91 - $6.36 $1.09 Million - $1.41 Million	221,486 Added 10.27%	2,378,738 $11.7 Million
Q4 2024 Feb 11, 2025	SELL	$4.49 - $6.85 $954,574 - $1.46 Million	-212,600 Reduced 8.97%	2,157,252 $11.2 Million
Q3 2024 Nov 14, 2024	SELL	$5.28 - $7.57 $2.91 Million - $4.18 Million	-551,811 Reduced 18.89%	2,369,852 $16.3 Million
Q2 2024 Aug 13, 2024	BUY	$5.89 - $9.31 $5.48 Million - $8.66 Million	930,185 Added 46.71%	2,921,663 $21.6 Million
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $5.37 Million - $8.64 Million	887,408 Added 80.38%	1,991,478 $14.5 Million
Q4 2023 Feb 13, 2024	SELL	$3.29 - $6.64 $542,234 - $1.09 Million	-164,813 Reduced 12.99%	1,104,070 $6.85 Million
Q3 2023 May 14, 2024	BUY	$3.3 - $4.83 $543,882 - $796,046	164,813 Added 14.93%	1,268,883 $5.18 Million
Q3 2023 Nov 14, 2023	SELL	$3.3 - $4.83 $441,675 - $646,452	-133,841 Reduced 9.54%	1,268,883 $5.18 Million
Q2 2023 May 14, 2024	SELL	$3.23 - $4.95 $827,726 - $1.27 Million	-256,262 Reduced 15.45%	1,402,724 $4.76 Million
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $827,726 - $1.27 Million	-256,262 Reduced 15.45%	1,402,724 $4.76 Million
Q1 2023 May 14, 2024	BUY	$2.68 - $4.79 $3.4 Million - $6.07 Million	1,266,814 Added 323.03%	1,658,986 $7.95 Million
Q1 2023 May 11, 2023	BUY	$2.68 - $4.79 $3.4 Million - $6.07 Million	1,266,814 Added 323.03%	1,658,986 $7.95 Million
Q4 2022 May 14, 2024	BUY	$1.22 - $2.85 $458,862 - $1.07 Million	376,117 Added 2342.68%	392,172 $1.12 Million
Q4 2022 Feb 13, 2023	BUY	$1.22 - $2.85 $458,862 - $1.07 Million	376,117 Added 2342.68%	392,172 $1.12 Million
Q3 2022 May 14, 2024	SELL	$0.59 - $1.44 $187,772 - $458,291	-318,258 Reduced 95.2%	16,055 $19,000
Q3 2022 Nov 10, 2022	SELL	$0.59 - $1.44 $187,772 - $458,291	-318,258 Reduced 95.2%	16,055 $0
Q2 2022 May 14, 2024	SELL	$0.51 - $1.17 $392,576 - $900,615	-769,757 Reduced 69.72%	334,313 $198,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $31,587 - $72,466	61,937 Added 22.74%	334,313 $198,000
Q1 2022 May 16, 2022	SELL	$0.65 - $1.18 $217,149 - $394,209	-334,076 Reduced 55.09%	272,376 $291,000
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $65,599 - $129,674	76,279 Added 14.39%	606,452 $667,000
Q3 2021 Nov 10, 2021	BUY	$1.27 - $8.17 $673,319 - $4.33 Million	530,173 New	530,173 $700,000

Others Institutions Holding ARDX

# of Institutions

222

Shares Held

167M

Call Options Held

517K

Put Options Held

1.61M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $1.01B
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Ardelyx, Inc. Transaction History